Dark

Check out our Dark Pool Levels

AVEO
AVEO Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Jan 19, 2023

15.00USD0.000%(0.00)247,877

Pre-market

0.00USD-100.000%(-15.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 20, 2022

08:00AM EST First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC GlobeNewswire Inc

Jan 6, 2022

07:50AM EST AVEO Pharmaceuticals Filed U.S. Patent Application #20220000858 'SE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER' Benzinga

Jan 5, 2022

08:06AM EST NiKang Therapeutics And AVEO Oncology Announce Clinical Trial Collaboration And Supply Agreement To Evaluate Combination Of NKT2152, A HIF2 Inhibitor, And FOTIVDA (tivozanib) For The Treatment Of Advanced Clear Cell Renal Cell Carcinoma Benzinga

Jan 4, 2022

08:05AM EST AVEO Oncology Announces Clinical Trial Collaboration And Supply Agreement With Merck KGaA, Darmstadt, Germany To Evaluate Ficlatuzumab And ERBITUX In Patients With Recurrent Or Metastatic HNSCC Benzinga

08:05AM EST AVEO Oncology(Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. GlobeNewswire Inc

08:00AM EST AVEO Oncology Announces Clinical Trial Collaboration and Supply GlobeNewswire Inc

Dec 22, 2021

08:00AM EST AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th. GlobeNewswire Inc

Dec 1, 2021

07:20AM EST AVEO Oncology Announces Appointment Of Jeb Ledell As Chief Operating Officer Benzinga

07:11AM EST AVEO Oncology Appoints Jeb Ledell As COO RTTNews

07:00AM EST AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer Business Wire

Nov 10, 2021

07:00AM EST AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences Business Wire

Nov 9, 2021

11:08AM EST AVEO Pharmaceuticals Q3 EPS $(0.30) Beats $(0.36) Estimate, Sales $15.17M Beat $13.80M Estimate Benzinga

Nov 8, 2021

04:07PM EST AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 1, 2021

07:00AM EDT AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 Business Wire

Sep 20, 2021

07:05AM EDT AVEO Oncology Says US FDA Grants Fast Track Designation To Ficlatuzumab For R/R Head And Neck Squamous Cell Carcinoma RTTNews

07:01AM EDT AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation By The U.S. FDA For The Treatment Of Relapsed Or Recurrent Head And Neck Squamous Cell Carcinoma Benzinga

Aug 30, 2021

07:00AM EDT AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences Business Wire

Aug 5, 2021

05:42PM EDT Recap: AVEO Pharmaceuticals Q2 Earnings Benzinga

04:09PM EDT AVEO Pharmaceuticals Q2 EPS $(0.40) Beats $(0.45) Estimate, Sales $6.70M Miss $8.94M Estimate Benzinga

04:05PM EDT AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:00AM EDT AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021 Business Wire

Jul 12, 2021

06:06AM EDT HC Wainwright & Co. Maintains Buy on AVEO Pharmaceuticals, Lowers Price Target to $19 Benzinga

Jul 8, 2021

04:06PM EDT AVEO Oncology To Hose Key Opinion Leader Webinar On FOTIVDA For Relapsed Or Refractory Renal Cell Carcinoma On July 16 Benzinga

04:05PM EDT AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA(r) (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma Business Wire

Jun 7, 2021

07:00AM EDT AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma Business Wire

May 25, 2021

07:00AM EDT AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference Business Wire

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:02PM EDT AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA(r) (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma Business Wire

05:01PM EDT AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC Business Wire

May 10, 2021

05:02PM EDT AVEO Pharmaceuticals Q1 EPS $(0.81) Misses $(0.55) Estimate, Sales $1.92M Beat $1.01M Estimate Benzinga

04:05PM EDT AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 3, 2021

07:00AM EDT AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021 Business Wire

Apr 16, 2021

07:04AM EDT AVEO Oncology Appoints Kevin Cullen To Board RTTNews

07:00AM EDT AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors Business Wire

Apr 8, 2021

10:57AM EDT AVEO Pharma US Patent & Trademark Office Abstract For Co.'s 'ANTI-GDF-15 ANTIBODIES' Benzinga

Mar 29, 2021

07:02AM EDT AVEO Oncology's FOTIVDA Added to the National Comprehensive Cancer Network Clinical Practice Guidelines Benzinga

07:00AM EDT AVEO Oncology Announces Addition of FOTIVDA(r) (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines Business Wire

Mar 26, 2021

04:01PM EDT AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares Business Wire

Mar 23, 2021

10:38PM EDT AVEO Oncology Prices Public Offering Of 6 Mln Shares At$8.00/shr RTTNews

10:32PM EDT AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock Business Wire

Mar 22, 2021

04:11PM EDT AVEO Announces Proposed Public Offering Of Common Stock RTTNews

04:01PM EDT AVEO Oncology Reports 5M Share Common Stock Offering Benzinga

07:16AM EDT AVEO Oncology Announces U.S. Commercial Availability Of FOTIVDA For Relapsed Or Refractory Advanced Renal Cell Carcinoma RTTNews

07:08AM EDT AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance Benzinga

07:00AM EDT AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA(r) (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance Business Wire

Mar 16, 2021

04:21PM EDT AVEO Pharmaceuticals Q4 EPS $(0.44) Down From $(0.28) YoY, Sales $886.00K Up From $764.00K YoY Benzinga

04:06PM EDT AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update Business Wire

Mar 15, 2021

10:41AM EDT AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights Benzinga

07:09AM EDT AVEO To Regain Rights To AV-203 In All Territories Outside RTTNews

07:03AM EDT AVEO Oncology To Regain Its Rights To AV-203 Outside Of North America RTTNews

07:00AM EDT AVEO Oncology to Regain Ex-North American Rights to AV-203 Business Wire

Mar 12, 2021

08:36AM EST Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer Benzinga

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

07:21AM EST AVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase RTTNews

07:06AM EST AVEO Collaborates With BMY To Evaluate FOTIVDA-OPDIVO In Phase 3 TiNivo-2 Trial In IO Relapsed Renal Cell Carcinoma RTTNews

07:00AM EST AVEO Oncology Reports Collab With Bristol Myers To Evaluate FOTIVDA In Combo With OPDIVO For Trial Of Relapsed Renal Cancer Carcinoma Treatment Benzinga

07:00AM EST AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA(r) (tivozanib) in Combination with OPDIVO(r) (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma Business Wire

Mar 11, 2021

04:14PM EST AVEO Oncology Reports Drawdown Of $20M Tranche Under Hercules Debt Facility Benzinga

04:05PM EST AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility Business Wire

02:43PM EST Thinking About Buying CPNG Stock, MDMP Stock Or AVEO Stock? Benzinga

10:04AM EST AVEO Pharmaceuticals shares were trading higher on the much-awaited FDA Approval for its Tivozanib in relapsed kidney cancer. Benzinga

08:29AM EST 10 Biggest Price Target Changes For Thursday Benzinga

08:21AM EST Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer Benzinga

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

06:31AM EST SVB Leerink Maintains Outperform on AVEO Pharmaceuticals, Raises Price Target to $18 Benzinga

Mar 10, 2021

05:55PM EST AVEO Pharmaceuticals Announces Appointment Of Mike Ferraresso To Chief Commercial Officer Benzinga

05:52PM EST AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer Business Wire

05:48PM EST Shares of AVEO Oncology (AVEO) jumped about 20% in extended trading hours Wednesday after the company announced that the FDA approved Fotivda (tivozanib) for the treatment of patients with relapsed or refractory advanced renal cell carcinoma. RTTNews

03:25PM EST AVEO Press Release Confirms FDA Approval Of FOTIVDA For Relapsed, Refractory Advanced Renal Cell Carcinoma Benzinga

03:25PM EST AVEO Oncology Announces U.S. FDA Approval of FOTIVDA(r) (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Business Wire

03:13PM EST AVEO Pharma Shares Resume Trading After 2nd Circuit Breaker Halt Benzinga

03:09PM EST AVEO Pharma Shares Resume Trading and Halted Again on a Circuit Breaker, Up 71% Following FDA Approval Benzinga

Mar 2, 2021

07:00AM EST AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 18, 2021

07:14AM EST AVEO Oncology To Participate At SVB Leerink Global Healthcare Conference Feb. 25 At 3:00 p.m. ET Benzinga

07:00AM EST AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference Business Wire

Feb 11, 2021

07:00AM EST AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Business Wire

Jan 20, 2021

07:08AM EST AVEO Oncology Announces Commitment For Incremental $10 Mln Loan In Addition To Current Tranched RTTNews

07:04AM EST AVEO Oncology Announces Commitment For Incremental $10M Loan In Addition To Current Tranched, $35M Debt Facility With Hercules Capital Benzinga

07:00AM EST AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital Business Wire

Jan 19, 2021

06:10AM EST SVB Leerink Maintains Outperform on AVEO Pharmaceuticals, Raises Price Target to $10 Benzinga

Jan 15, 2021

08:22AM EST AVEO Oncology Announces Results From Phase 1b Portion Of DEDUCTIVE Study Of Tivozanib In Combination With IMFINZI In Previously Untreated Metastatic Hepatocellular Carcinoma Benzinga

08:19AM EST AVEO Oncology Announces Results From Phase 1b Portion Of DEDUCTIVE Study Of Tivozanib In Combination With IMFINZI RTTNews

08:01AM EST AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA(r)) in Combination with IMFINZI(r) (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Business Wire

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 9, 2021

01:02PM EST The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off Benzinga

Jan 7, 2021

07:30AM EST AVEO Oncology Highlights Recent Progress And Outlines 2021 Outlook RTTNews

07:10AM EST AVEO Oncology Highlights Recent Progress And 2021 Outlook Benzinga

Jan 6, 2021

07:00AM EST AVEO Oncology Announces Participation at Two Upcoming Investor Conferences Business Wire

Jan 5, 2021

07:00AM EST AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Nov 10, 2020

07:00AM EST AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference Business Wire

Nov 9, 2020

05:10PM EST Aveo Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300M Benzinga

04:28PM EST AVEO Pharmaceuticals Q3 Sales $3.60M Down From $25.72M YoY Benzinga

04:06PM EST AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

Nov 5, 2020

07:00AM EST AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma Business Wire

Oct 19, 2020

07:00AM EDT AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales Business Wire

Sep 15, 2020

06:53PM EDT After Hours Market: Myomo, FedEx, Inovio Pharmaceuticals, RTTNews

04:11PM EDT AVEO Oncology Announces That The European Urology Publication Of Final Overall Survival Data From Its Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Benzinga

04:05PM EDT AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Business Wire

Sep 8, 2020

07:06AM EDT AVEO Oncology Regains Full Global Rights to Ficlatuzumab Benzinga

Sep 3, 2020

07:00AM EDT AVEO Oncology Announces Participation at Two Upcoming Investor Conferences Business Wire

Aug 13, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For August 13, 2020 Benzinga

06:20AM EDT SVB Leerink Initiates Coverage On AVEO Pharmaceuticals with Outperform Rating, Announces Price Target of $7 Benzinga

Aug 10, 2020

04:41PM EDT AVEO Pharmaceuticals Q2 EPS $(0.42) Down From $(0.02) YoY, Sales $749.00K Up From $703.00K YoY Benzinga

04:05PM EDT AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

04:05PM EDT AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility Business Wire

Aug 5, 2020

04:20PM EDT AVEO Oncology Reports $2.8M Development Milestone Earned From Kyowa Kirin Benzinga

04:05PM EDT AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin Business Wire

Share